MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024
Portfolio Pulse from
MDxHealth SA reported a significant increase in test volumes and raised its 2024 revenue guidance, indicating strong growth. The company has also announced a conference call to discuss these results.
November 06, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MDxHealth SA reported a 36% increase in tissue-based test volumes and a 24% increase in liquid-based test volumes. The company raised its 2024 revenue guidance to $87-89 million, representing a 25% growth. Pro-forma cash stands at $53.5 million.
The significant increase in test volumes and the raised revenue guidance suggest strong business performance and growth potential, likely leading to a positive impact on the stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100